Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Liabilities (2023 - 2025)

Beta Bionics' Total Liabilities history spans 3 years, with the latest figure at $41.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 44.14% year-over-year to $41.1 million; the TTM value through Dec 2025 reached $41.1 million, down 44.14%, while the annual FY2025 figure was $41.1 million, 44.14% down from the prior year.
  • Total Liabilities for Q4 2025 was $41.1 million at Beta Bionics, up from $35.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $228.8 million in Q3 2024 and bottomed at $24.3 million in Q1 2025.
  • The 3-year median for Total Liabilities is $51.4 million (2023), against an average of $102.1 million.
  • The largest annual shift saw Total Liabilities soared 43.16% in 2024 before it tumbled 88.68% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $51.4 million in 2023, then skyrocketed by 43.16% to $73.6 million in 2024, then tumbled by 44.14% to $41.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Total Liabilities are $41.1 million (Q4 2025), $35.3 million (Q3 2025), and $28.3 million (Q2 2025).